Consolidation of the Shin-Yokohama and Osaka Cell Processing Facilities into the Shinagawa CPF
First written in FY2018-Q2. 2 of 4 entries say "Restated". Latest entry: FY2019-Q2.
No other company in this theme has enough history to compare yet.
- FY2019-Q2AchievedAnnual report
「The Shin-Yokohama and Osaka cell culture processing facilities were consolidated by March 2019 into the Shinagawa Cell Culture Processing Facility, which has one of the largest production capacities in Japan.」
The Company states that the Shin-Yokohama and Osaka cell culture processing facilities were consolidated into the Shinagawa CPF by March 2019. - FY2019-Q1RestatedAnnual report
「The Shin-Yokohama and Osaka cell culture processing facilities will be consolidated by March 2019 into the Shinagawa Cell Culture Processing Facility, which has one of the largest production capacities in Japan. By conducting both cell processing for physicians and the manufacture of regenerative medicine products there, the Company aims to improve the efficiency of its production structure and achieve break-even earnings in the cell processing business segment in the fiscal year ending September 2019.」
The Company continues to pursue its plan to consolidate the Shin-Yokohama and Osaka facilities into the Shinagawa CPF by March 2019 and achieve break-even earnings in the fiscal year ending September 2019. - FY2018-Q3RestatedAnnual report
「The Shin-Yokohama and Osaka cell culture processing facilities will be consolidated by March 2019 into the Shinagawa Cell Culture Processing Facility, which has one of the largest production capacities in Japan. By conducting both cell processing and the manufacture of regenerative medicine products there, the Company aims to improve the efficiency of its production structure.」
The Company continues to pursue its plan to consolidate the Shin-Yokohama and Osaka facilities into the Shinagawa CPF by March 2019. - FY2018-Q2First statedAnnual report
「We will consolidate the Shin-Yokohama and Osaka cell culture and processing facilities at the Shinagawa cell culture and processing facility, which has one of the largest manufacturing capacities in Japan, by around March 2019. By carrying out both cell processing for physicians and the manufacture of regenerative medical products, we will improve the efficiency of our manufacturing system.」
The Company initially presented a plan to consolidate the 2 facilities in Shin-Yokohama and Osaka at Shinagawa CPF by around March 2019 and integrate physician-directed cell processing with regenerative medical product manufacturing.